Toniiq Glutathione delivers reduced glutathione at a 98%+ purity level high for the category, where many products don't disclose purity
Beyond cosmetics, the therapeutic potential of GHK-Cu is a major focus in regenerative medicine
Business Type Exporter, Importer, Manufacturer, Supplier Related Products Explore Related Categories More Products From This Seller Seller Details GST - 24AIRPL2393L1ZP 5 Rating Accepts only Foreign inquiries 418, Sky View, Sarthana Kamrej Main Road, Sarthana, Surat, Gujarat, 395006, India pharmaceutical injection in Surat Compare With Similar Products Price Or Price Range 13200.0 INR (Approx.) 19500.0 INR (Approx.) Salt Composition GHRP-6 acetate, CJC-1295 without DAC acetate Recombinant GDF-8 analogue Indication Muscle building, muscle recovery, performance improvement Primary indication for advanced muscle wasting therapies and research Dosage Form Injection (after reconstitution from lyophilized powder) Injection Pacakaging (Quantity Per Box) 2 vials per box, sealed packaging 1 vial per box Origin Of Medicine Synthetic/Pharmaceutical Biotechnological synthesis Drug Type Other, Peptide hormones/stimulants Other, Biological injectable Ingredients GHRP-6 (Growth Hormone Releasing Peptide 6), CJC-1295 (without DAC), sterile water (solvent) Recombinant Myostatin (GDF-8) analogues, sterile water for injection, stabilizing agents Physical Form Other, Lyophilized powder Liquid Function Other, Promotes growth hormone release, supports muscle growth and tissue repair Other, Promotes muscle hypertrophy by inhibiting myostatin activity Recommended For Muscle building, recovery, peptide therapy enthusiasts, fitness athletes Muscle growth, performance enhancement, research purposes Dosage Typically 100 mcg of each (GHRP-6 and CJC-1295) per administration, 1-3 times daily, subcutaneous injection 1 mg per vial (as per vial marking) Dosage Guidelines Subcutaneous injection only
If the question is about repeated signaling, split administration may make more sense than a one-time daily exposure
In addition, the development cycles are long and the success rate is low, which are critical factors restricting drug development
Theoretical and Class-Level Risks These have not been confirmed in cagrilintide trials but are flagged because they appear in related amylin or GLP-1 class data: pancreatitis, gallbladder disease, severe hypoglycemia (mainly when combined with insulin or sulfonylureas), and acute kidney injury secondary to dehydration from severe nausea or vomiting
